Inozyme Pharma Focuses on ENPP1 Deficiency Program

Inozyme Pharma, Inc. ( (INZY) ) has released its Q4 earnings. Here is a breakdown of the information Inozyme Pharma, Inc. presented to its investors.

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases affecting bone health and blood vessel function, with a particular emphasis on the PPi-Adenosine Pathway.

In its latest financial report, Inozyme Pharma highlighted significant progress in its ENPP1 Deficiency program, including the completion of enrollment in the pivotal ENERGY 3 trial and promising interim data from the ENERGY 1 trial. The company also announced strategic measures to extend its operational runway, including a 25% workforce reduction.

Key financial metrics from 2024 show a cash position of $113.1 million, with research and development expenses rising to $83.2 million, reflecting increased clinical development and preparation for potential commercialization. The company’s net loss widened to $102.0 million, or $1.62 per share, compared to the previous year.

Strategically, Inozyme is prioritizing its ENPP1 Deficiency program, postponing other trials to focus resources on advancing INZ-701 toward potential approval. This decision is expected to extend the company’s cash runway into early 2026, despite the challenging organizational changes.

Looking ahead, Inozyme Pharma remains committed to advancing its lead program, INZ-701, as a potential treatment for ENPP1 Deficiency, with topline data from the pivotal trial anticipated in the first quarter of 2026, positioning the company for future growth and development in the rare disease sector.